Prostate Cancer

Ruben Olivares, MD, discusses the functional advantages of using focal therapy over localized radiation in prostate cancer.

Alicia Morgans, MD, MPH, discusses the use of ADT in combination with darolutamide or placebo in nonmetastatic castration-resistant prostate cancer.

Ruben Olivares, MD, discusses considerations for managing prostate cancer in the community setting, particularly regarding early detection and screening.

Carmen Guerra, MD, MSCE, FACP, discusses the implications of research into the rates of prostate cancer screening in a population of diverse men.

The FDA has granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions.

Olaparib produced responses in high-risk, biochemically recurrent prostate cancer with HRR alterations, particularly BRCA2 alterations.

Males harboring BRCA1/2 pathologic variants have a higher risk of developing select cancers but are less likely to undergo genetic testing.

Enzalutamide led to improved OS, PCS, TTS, and TTR vs abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

Praful Ravi, MB, BChir, MRCP, discusses an analysis measuring residual cancer burden in localized prostate cancer after neoadjuvant therapy and surgery.

Jun Gong, MD, discusses the benefits and limitations of PARP inhibitor–based regimens in metastatic castration-resistant prostate cancer.

Alicia Morgans, MD, MPH, discusses key data from the follow-up analysis of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

The FDA has accepted the new drug application for the new TLX007-CDx cold kit for the preparation of PSMA-PET imaging in patients with prostate cancer.

Marc-Oliver Grimm, MD, discusses a post-hoc analysis of the ARASENS trial in metastatic hormone-sensitive prostate cancer.

Alicia Morgans, MD, MPH, discusses data from the ARAMIS trial showing the association between PSA levels and radiological progression in nmCRPC.

Experts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment.

Key opinion leaders outline a case study of a patient with metastatic castration-sensitive prostate cancer, detailing the chosen treatment approaches and the overall outcome of the case.

Darolutamide plus ADT improved radiologic PFS vs placebo plus ADT in men with metastatic hormone-sensitive prostate cancer enrolled in the phase 3 ARANOTE trial.

Jun Gong, MD, discusses the importance of molecular profiling when determining optimal treatments for patients with mCRPC.

Marc-Oliver Grimm, MD discusses the clinical implications, short comings, and future steps following a post-hoc analysis from the phase 3 ARASENS trial.

A 100-mg dose of tarlatamab was safe and showed particularly robust activity in patients with DLL3-positive neuroendocrine prostate cancer.

Experts present a case study of a patient with non-metastatic castration-sensitive prostate cancer exhibiting rapid PSA doubling, highlighting the clinical implications and potential treatment considerations.

Specialists examine non-metastatic castration-sensitive prostate cancer cases, evaluating the significance of PSA doubling time and the reliability of biomarkers in risk assessment for these patients.

The FDA has granted fast track designation to BNT324/DB-1311 for metastatic castration-resistant prostate cancer.

S. Lindsey Davis, MD, highlights data with the mTOR inhibitor sapanisertib and Aurora A kinase inhibitor alisertib in patients with solid tumors.

Atish D. Choudhury, MD, PhD, on the potential of future trials to investigate treatment interruption in metastatic hormone-sensitive prostate cancer.